Thalamic Kv 7 channels: pharmacological properties and activity control during noxious signal processing

Br J Pharmacol. 2015 Jun;172(12):3126-40. doi: 10.1111/bph.13113. Epub 2015 Apr 10.

Abstract

Background and purpose: The existence of functional K(v)7 channels in thalamocortical (TC) relay neurons and the effects of the K(+)-current termed M-current (I(M)) on thalamic signal processing have long been debated. Immunocytochemical evidence suggests their presence in this brain region. Therefore, we aimed to verify their existence, pharmacological properties and function in regulating activity in neurons of the ventrobasal thalamus (VB).

Experimental approach: Characterization of K(v)7 channels was performed by combining in vitro, in vivo and in silico techniques with a pharmacological approach. Retigabine (30 μM) and XE991 (20 μM), a specific K(v)7 channel enhancer and blocker, respectively, were applied in acute brain slices during electrophysiological recordings. The effects of intrathalamic injection of retigabine (3 mM, 300 nL) and/or XE991 (2 mM, 300 nL) were investigated in freely moving animals during hot-plate tests by recording behaviour and neuronal activity.

Key results: K(v)7.2 and K(v)7.3 subunits were found to be abundantly expressed in TC neurons of mouse VB. A slow K(+)-current with properties of IM was activated by retigabine and inhibited by XE991. K(v)7 channel activation evoked membrane hyperpolarization, a reduction in tonic action potential firing, and increased burst firing in vitro and in computational models. Single-unit recordings and pharmacological intervention demonstrated a specific burst-firing increase upon I(M) activation in vivo. A K(v)7 channel-mediated increase in pain threshold was associated with fewer VB units responding to noxious stimuli, and increased burst firing in responsive neurons.

Conclusions and implications: K(v)7 channel enhancement alters somatosensory activity and may reflect an anti-nociceptive mechanism during acute pain processing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Acute Pain / physiopathology*
  • Animals
  • Anthracenes / pharmacology
  • Brain / drug effects
  • Brain / metabolism
  • Carbamates / pharmacology
  • Disease Models, Animal
  • KCNQ Potassium Channels / metabolism*
  • KCNQ2 Potassium Channel / metabolism
  • KCNQ3 Potassium Channel / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Neurons / drug effects
  • Pain Threshold / physiology
  • Phenylenediamines / pharmacology
  • Thalamus / drug effects*
  • Thalamus / metabolism

Substances

  • 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone
  • Anthracenes
  • Carbamates
  • KCNQ Potassium Channels
  • KCNQ2 Potassium Channel
  • KCNQ3 Potassium Channel
  • Phenylenediamines
  • ezogabine